Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in Gut Retrieve available abstracts of 114 articles: HTML format

Single Articles

September 2025
1. CARLESSI R, Kendall TJ, Olynyk JK, Dwyer BJ, et al
   Disease-associated hepatocytes are predictive of outcomes and survival in MASLD beyond fibrosis staging.
   Gut. 2025 Sep 10:gutjnl-2025-336627. doi: 10.1136/gutjnl-2025-336627.
   PubMed    
   
   
   
2. FENG G, Wong VW, Targher G, Byrne CD, et al
   Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring.
   Gut. 2025;74:1741-1750.
   PubMed     Abstract available
   
   
   
3. BU L, Zhang Y, Su Y, Wu X, et al
   High-protein diets alleviate tumour growth and drug resistance by promoting AKT aggregation and turnover.
   Gut. 2025;74:1711-1727.
   PubMed     Abstract available
   
   
   
4. MA L, Hung MH, Rashidi Mehrabadi F, Wang L, et al
   Beneficial infections of the enterovirus genus in patients with liver cancer.
   Gut. 2025;74:1667-1679.
   PubMed     Abstract available
   
   
   
5. CHAN M, Zhu S, Nukaya M, Ferreira LT, et al
   DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma.
   Gut. 2025;74:1680-1693.
   PubMed     Abstract available
   
   
   August 2025
6. MILARDI G, Franceschini B, Camisaschi C, Puccio S, et al
   Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome.
   Gut. 2025 Aug 31:gutjnl-2025-334861. doi: 10.1136/gutjnl-2025-334861.
   PubMed     Abstract available
   
   
   
7. YUAN Y, Li J, Rao D, Lu X, et al
   ISG15 deficiency in hepatic stellate cells promotes TGFbeta2-induced liver fibrosis by counteracting CREB1 ISGylation.
   Gut. 2025 Aug 17:gutjnl-2025-335327. doi: 10.1136/gutjnl-2025-335327.
   PubMed     Abstract available
   
   
   
8. LUCAS-RUIZ F, Vidal-Correoso D, Mateo SV, de la Torre-Alamo MM, et al
   Intrahepatic donor microbiota-based metataxonomic signature detected in organ preservation solution enables prediction of short-term liver transplant outcomes.
   Gut. 2025 Aug 12:gutjnl-2025-335986. doi: 10.1136/gutjnl-2025-335986.
   PubMed     Abstract available
   
   
   
9. WU X, Quan D, Li W, Wisskirchen K, et al
   Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.
   Gut. 2025 Aug 12:gutjnl-2025-335456. doi: 10.1136/gutjnl-2025-335456.
   PubMed     Abstract available
   
   
   
10. FONTANELLAS A, Berraondo P, Urigo F, Jerico D, et al
    RNA-based therapies in liver metabolic diseases.
    Gut. 2025;74:1514-1527.
    PubMed     Abstract available
    
    
    
11. 
    Correction: Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
    Gut. 2025;74:e18.
    PubMed    
    
    
    July 2025
12. PRAWIRA A, Xu H, Mei Y, Nasir NJM, et al
    Targeting Treg-fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma.
    Gut. 2025 Jul 22:gutjnl-2025-335084. doi: 10.1136/gutjnl-2025-335084.
    PubMed     Abstract available
    
    
    
13. GUILLOT A, Pose E
    Hepatocyte senescence in alcohol-associated hepatitis: epiphenomenon or disease-driving mechanism?
    Gut. 2025 Jul 17:gutjnl-2025-335271. doi: 10.1136/gutjnl-2025-335271.
    PubMed    
    
    
    June 2025
14. NIU J, Gao Y, Wang G, Qin Z, et al
    Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial.
    Gut. 2025 Jun 24:gutjnl-2025-335577. doi: 10.1136/gutjnl-2025-335577.
    PubMed     Abstract available
    
    
    
15. LAI JC, Yang B, Lee HW, Lin H, et al
    Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2025 Jun 20:gutjnl-2025-334981. doi: 10.1136/gutjnl-2025-334981.
    PubMed     Abstract available
    
    
    
16. CHEN J, Xu X, Yang S, Yu X, et al
    Validation of the CLIF-SIG score in patients with HBV-related acutely decompensated cirrhosis.
    Gut. 2025 Jun 19:gutjnl-2025-335810. doi: 10.1136/gutjnl-2025-335810.
    PubMed    
    
    
    
17. GOUGELET A
    NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression.
    Gut. 2025 Jun 15:gutjnl-2025-335795. doi: 10.1136/gutjnl-2025-335795.
    PubMed    
    
    
    
18. DE MARTIN E, Fulgenzi CAM, Celsa C, Laurent-Bellue A, et al
    Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events.
    Gut. 2025;74:1165-1177.
    PubMed     Abstract available
    
    
    
19. LI S, Fu Y, Jia X, Liu Z, et al
    NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression.
    Gut. 2025 Jun 5:gutjnl-2024-334448. doi: 10.1136/gutjnl-2024-334448.
    PubMed     Abstract available
    
    
    
20. XING X, Wang SD, Yang JL, Wang Z, et al
    Presinusoidal portal hypertension with cutaneous vascular malformations.
    Gut. 2025 Jun 2:gutjnl-2025-335640. doi: 10.1136/gutjnl-2025-335640.
    PubMed    
    
    
    May 2025
21. ROSNER T, Rupp C, Lechler C, Bauer U, et al
    Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer.
    Gut. 2025 May 12:gutjnl-2024-333238. doi: 10.1136/gutjnl-2024-333238.
    PubMed     Abstract available
    
    
    
22. WANG C, Felli E, Fallowfield JA, Dietrich CF, et al
    Vasomics of the liver.
    Gut. 2025;74:1008-1020.
    PubMed     Abstract available
    
    
    April 2025
23. PINTER M, Fulgenzi CAM, Pinato DJ, Scheiner B, et al
    Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction.
    Gut. 2025 Apr 29:gutjnl-2025-334928. doi: 10.1136/gutjnl-2025-334928.
    PubMed     Abstract available
    
    
    
24. MACCIONI L, Guan Y, Kim M, Parra MA, et al
    Opposite regulation of intestinal and intrahepatic CD8(+) T cells controls alcohol-associated liver disease progression.
    Gut. 2025 Apr 8:gutjnl-2024-334412. doi: 10.1136/gutjnl-2024-334412.
    PubMed     Abstract available
    
    
    
25. CELSA C, Pennisi G, Tulone A, Ciancimino G, et al
    Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.
    Gut. 2025;74:815-824.
    PubMed     Abstract available
    
    
    
26. JIA Q, Sun X, Li H, Guo J, et al
    Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges.
    Gut. 2025;74:840-852.
    PubMed     Abstract available
    
    
    March 2025
27. XU H, Wu Z, Qin J, Li X, et al
    Stressed hepatocyte sustains alcohol-associated hepatitis progression by producing leukocyte cell-derived chemotaxin 2.
    Gut. 2025 Mar 26:gutjnl-2024-334318. doi: 10.1136/gutjnl-2024-334318.
    PubMed     Abstract available
    
    
    
28. GOYAL NP, Xanthakos S, Schwimmer JB
    Metabolic dysfunction-associated steatotic liver disease in children.
    Gut. 2025;74:669-677.
    PubMed     Abstract available
    
    
    
29. LI G, He J, Shi J, Li X, et al
    Bioprinting functional hepatocyte organoids derived from human chemically induced pluripotent stem cells to treat liver failure.
    Gut. 2025 Mar 3:gutjnl-2024-333885. doi: 10.1136/gutjnl-2024-333885.
    PubMed     Abstract available
    
    
    February 2025
30. ZHANG Z, Huang W, Hu D, Jiang J, et al
    E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression.
    Gut. 2025 Feb 27:gutjnl-2024-333944. doi: 10.1136/gutjnl-2024-333944.
    PubMed     Abstract available
    
    
    
31. TREBICKA J, Aguilar F, Queiroz Farias A, Lozano JJ, et al
    Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
    Gut. 2025 Feb 26:gutjnl-2024-333876. doi: 10.1136/gutjnl-2024-333876.
    PubMed     Abstract available
    
    
    
32. MYOJIN Y, Babaei S, Trehan R, Hoffman C, et al
    Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab.
    Gut. 2025 Feb 18:gutjnl-2024-334026. doi: 10.1136/gutjnl-2024-334026.
    PubMed     Abstract available
    
    
    
33. TARGHER G, Mantovani A, Byrne CD, Tilg H, et al
    Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.
    Gut. 2025;74:487-497.
    PubMed     Abstract available
    
    
    January 2025
34. MARAVELIA P, Yao H, Cai C, Nascimento Silva D, et al
    Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation.
    Gut. 2025 Jan 19:gutjnl-2024-334148. doi: 10.1136/gutjnl-2024-334148.
    PubMed     Abstract available
    
    
    
35. CORDOBA KM, Jerico D, Jiang L, Collantes M, et al
    Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates.
    Gut. 2025;74:270-283.
    PubMed     Abstract available
    
    
    
36. GHOSH S, Zhao X, Alim M, Brudno M, et al
    Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment.
    Gut. 2025;74:295-311.
    PubMed     Abstract available
    
    
    
37. YANG Y, Pei T, Liu C, Cao M, et al
    Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A(+) myeloid cells to promote liver cancer progression.
    Gut. 2025;74:255-269.
    PubMed     Abstract available
    
    
    December 2024
38. ZHANG Y, Xie M, Wen J, Liang C, et al
    Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy.
    Gut. 2024 Dec 12:gutjnl-2024-333154. doi: 10.1136/gutjnl-2024-333154.
    PubMed     Abstract available
    
    
    
39. CHEN J, Jiang Y, Hou M, Liu C, et al
    Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC.
    Gut. 2024;74:128-140.
    PubMed     Abstract available
    
    
    November 2024
40. MAO X, Zhang X, Kam L, Chien N, et al
    Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024;73:2054-2061.
    PubMed     Abstract available
    
    
    
41. SINGAL AG, Narasimman M, Daher D, Yekkaluri S, et al
    Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial.
    Gut. 2024;73:2037-2044.
    PubMed     Abstract available
    
    
    
42. TU Y, Wu H, Zhong C, Liu Y, et al
    Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma.
    Gut. 2024 Nov 1:gutjnl-2024-332281. doi: 10.1136/gutjnl-2024-332281.
    PubMed     Abstract available
    
    
    October 2024
43. VAN DER MERWE SW, G Fernandez-Barrena M
    Safe and successful gut-restricted adsorbent strategy against cirrhosis and acute-on-chronic liver failure.
    Gut. 2024 Oct 26:gutjnl-2024-332457. doi: 10.1136/gutjnl-2024-332457.
    PubMed    
    
    
    
44. LINK F, Li Y, Zhao J, Munker S, et al
    ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-beta1 activation.
    Gut. 2024 Oct 24:gutjnl-2024-333213. doi: 10.1136/gutjnl-2024-333213.
    PubMed     Abstract available
    
    
    
45. SALIE H, Wischer L, D'Alessio A, Godbole I, et al
    Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma.
    Gut. 2024 Oct 14:gutjnl-2024-332837. doi: 10.1136/gutjnl-2024-332837.
    PubMed     Abstract available
    
    
    
46. PAN DZ, Soulette CM, Aggarwal A, Han D, et al
    Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B.
    Gut. 2024 Oct 8:gutjnl-2024-332526. doi: 10.1136/gutjnl-2024-332526.
    PubMed     Abstract available
    
    
    
47. ZHOU XD, Kim SU, Yip TC, Petta S, et al
    Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
    Gut. 2024;73:1883-1892.
    PubMed     Abstract available
    
    
    
48. SHANG Y, Akbari C, Dodd M, Nasr P, et al
    Cause of death by fibrosis stage in 959 patients with biopsy-proven NAFLD.
    Gut. 2024;73:e30.
    PubMed    
    
    
    
49. 
    Correction: Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2024;73:e32.
    PubMed    
    
    
    September 2024
50. ZIPPRICH A, Hernaez R
    High-risk varices in patients with Child-Pugh-Turcotte B and C: consider band ligation with carvedilol for preventing first variceal bleeding, especially in patients with MASLD-associated cirrhosis.
    Gut. 2024 Sep 18:gutjnl-2024-333263. doi: 10.1136/gutjnl-2024-333263.
    PubMed    
    
    
    
51. YOU W, Hu C, Zhao M, Zhang Y, et al
    Extending inflamed-class signature to predict immune checkpoint inhibitor-based combination therapy in hepatocellular carcinoma.
    Gut. 2024 Sep 11:gutjnl-2024-333375. doi: 10.1136/gutjnl-2024-333375.
    PubMed    
    
    
    
52. BEA S, Ko HY, Bae JH, Cho YM, et al
    Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024 Sep 6:gutjnl-2024-332687. doi: 10.1136/gutjnl-2024-332687.
    PubMed     Abstract available
    
    
    August 2024
53. CHEN J, Xu Y, Lin Y, Wang C, et al
    Hepatomegaly and ascites in a patient with UC.
    Gut. 2024 Aug 30:gutjnl-2024-333587. doi: 10.1136/gutjnl-2024-333587.
    PubMed    
    
    
    
54. DUBOIS V, Lefebvre P, Staels B, Eeckhoute J, et al
    Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease.
    Gut. 2024;73:1562-1569.
    PubMed     Abstract available
    
    
    
55. MANTOVANI A, Csermely A, Bilson J, Borella N, et al
    Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis.
    Gut. 2024;73:1554-1561.
    PubMed     Abstract available
    
    
    
56. YANG AH, Tincopa MA, Tavaglione F, Ajmera VH, et al
    Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA.
    Gut. 2024 Aug 7:gutjnl-2024-332917. doi: 10.1136/gutjnl-2024-332917.
    PubMed     Abstract available
    
    
    
57. HEINRICH B, Cubero FJ
    FTO/m6A/GPNMB axis: a novel promising target for hepatocellular carcinoma (HCC) treatment?
    Gut. 2024 Aug 1:gutjnl-2024-332934. doi: 10.1136/gutjnl-2024-332934.
    PubMed    
    
    
    July 2024
58. TEVETHIA HV, Pande A, Vijayaraghavan R, Kumar G, et al
    Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
    Gut. 2024 Jul 27:gutjnl-2023-331181. doi: 10.1136/gutjnl-2023-331181.
    PubMed     Abstract available
    
    
    
59. CAMPANI C, Imbeaud S, Couchy G, Ziol M, et al
    Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
    Gut. 2024 Jul 25:gutjnl-2024-331956. doi: 10.1136/gutjnl-2024-331956.
    PubMed     Abstract available
    
    
    
60. WANG Y, Heymann F, Peiseler M
    Intravital imaging: dynamic insights into liver immunity in health and disease.
    Gut. 2024;73:1364-1375.
    PubMed     Abstract available
    
    
    
61. LOOMBA R, Amangurbanova M, Bettencourt R, Madamba E, et al
    MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH.
    Gut. 2024;73:1343-1349.
    PubMed     Abstract available
    
    
    June 2024
62. HA S, Wong VW, Zhang X, Yu J, et al
    Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.
    Gut. 2024 Jun 29:gutjnl-2024-332398. doi: 10.1136/gutjnl-2024-332398.
    PubMed     Abstract available
    
    
    
63. KEGGENHOFF FL, Castven D, Becker D, Stojkovic S, et al
    PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.
    Gut. 2024 Jun 10:gutjnl-2023-331237. doi: 10.1136/gutjnl-2023-331237.
    PubMed     Abstract available
    
    
    
64. BU L, Zhang Z, Chen J, Fan Y, et al
    High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT.
    Gut. 2024;73:1156-1168.
    PubMed     Abstract available
    
    
    
65. NISCHALKE HD, Nischalke C, Schmalz F, Moller C, et al
    Catecholamines and inflammation in advanced liver disease: more closely intertwined than expected?
    Gut. 2024;73:1219-1222.
    PubMed    
    
    
    
66. CHEN A, Zhang VX, Zhang Q, Sze KM, et al
    Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma.
    Gut. 2024 Jun 5:gutjnl-2024-331903. doi: 10.1136/gutjnl-2024-331903.
    PubMed     Abstract available
    
    
    May 2024
67. BABUTA M, Morel C, de Carvalho Ribeiro M, Calenda C, et al
    Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis.
    Gut. 2024 May 22:gutjnl-2023-331447. doi: 10.1136/gutjnl-2023-331447.
    PubMed     Abstract available
    
    
    
68. WEN J, Zhang X, Wong CC, Zhang Y, et al
    Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma.
    Gut. 2024 May 13:gutjnl-2023-331117. doi: 10.1136/gutjnl-2023-331117.
    PubMed     Abstract available
    
    
    
69. GEIER A, Trost J, Wang K, Schmid C, et al
    PNPLA3 fatty liver allele was fixed in Neanderthals and segregates neutrally in humans.
    Gut. 2024;73:1008-1014.
    PubMed     Abstract available
    
    
    
70. ISRAELSEN M, Alvarez-Silva C, Madsen BS, Hansen CD, et al
    Impact of acute alcohol consumption on circulating microbiome in asymptomatic alcohol-related liver disease.
    Gut. 2024;73:1041-1044.
    PubMed    
    
    
    
71. ROCA SUAREZ AA, Plissonnier ML, Grand X, Michelet M, et al
    TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism.
    Gut. 2024 May 2:gutjnl-2023-331396. doi: 10.1136/gutjnl-2023-331396.
    PubMed     Abstract available
    
    
    April 2024
72. BREITKOPF-HEINLEIN K, Martinez-Chantar ML
    Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?
    Gut. 2024 Apr 25:gutjnl-2023-331785. doi: 10.1136/gutjnl-2023-331785.
    PubMed    
    
    
    
73. 
    Correction: Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
    Gut. 2024 Apr 23:gutjnl-2016-312278corr1. doi: 10.1136/gutjnl-2016-312278.
    PubMed    
    
    
    
74. SUDDLE A, Reeves H, Hubner R, Marshall A, et al
    British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.
    Gut. 2024 Apr 16:gutjnl-2023-331695. doi: 10.1136/gutjnl-2023-331695.
    PubMed     Abstract available
    
    
    
75. LIU J, MacNaughtan J, Kerbert AJC, Portlock T, et al
    Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis.
    Gut. 2024 Apr 15:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699.
    PubMed     Abstract available
    
    
    
76. SUISSA S, Hernaez R
    Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity?
    Gut. 2024;73:721-724.
    PubMed    
    
    
    
77. LIU B, Peng G, Yin Y, Shen C, et al
    Genetic evidence for repurposing of glucagon-like peptide-1 receptor agonists to prevent chronic liver diseases.
    Gut. 2024;73:879-882.
    PubMed    
    
    
    
78. WESTER A, Shang Y, Toresson Grip E, Matthews AA, et al
    Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.
    Gut. 2024;73:835-843.
    PubMed     Abstract available
    
    
    
79. ARMANDI A, Sanavia T, Younes R, Caviglia GP, et al
    Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024;73:825-834.
    PubMed     Abstract available
    
    
    March 2024
80. TREBICKA J, Hernaez R, Shawcross DL, Gerbes AL, et al
    Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
    Gut. 2024 Mar 25:gutjnl-2023-330584. doi: 10.1136/gutjnl-2023-330584.
    PubMed     Abstract available
    
    
    
81. HILDT E, Hu J
    New facet of CARs: HBV-specific CARs as inhibitors of virus morphogenesis and release.
    Gut. 2024;73:566-567.
    PubMed    
    
    
    
82. TARGHER G, Byrne CD, Tilg H
    MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Gut. 2024;73:691-702.
    PubMed     Abstract available
    
    
    February 2024
83. LEE HH, Lee HA, Kim EJ, Kim HY, et al
    Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Gut. 2024;73:533-540.
    PubMed     Abstract available
    
    
    
84. CUBERO FJ, Sarobe P, Tiegs G
    Advancing with cancer immunotherapeutics: CD29(+) regulatory T cell antagonism.
    Gut. 2024;73:391-392.
    PubMed    
    
    
    
85. GREEN BL, Myojin Y, Ma C, Ruf B, et al
    Immunosuppressive CD29(+) Treg accumulation in the liver in mice on checkpoint inhibitor therapy.
    Gut. 2024;73:509-520.
    PubMed     Abstract available
    
    
    
86. HUNTER H, Johnston AJ, Said W, Wong NA, et al
    Colonic spider naevi in a middle-aged man.
    Gut. 2024;73:441-520.
    PubMed    
    
    
    
87. QIAN Z, Liang J, Huang R, Song W, et al
    HBV integrations reshaping genomic structures promote hepatocellular carcinoma.
    Gut. 2024 Feb 23:gutjnl-2023-330414. doi: 10.1136/gutjnl-2023-330414.
    PubMed     Abstract available
    
    
    
88. EL-SERAG H, Kanwal F, Ning J, Powell H, et al
    Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
    Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
    PubMed     Abstract available
    
    
    
89. KEATING CR, Calvisi DF, Qiu W
    High-fat diet-induced AKT-palmitoylation in hepatocellular carcinoma: a breakthrough mechanistic investigation.
    Gut. 2024 Feb 9:gutjnl-2023-331857. doi: 10.1136/gutjnl-2023-331857.
    PubMed    
    
    
    January 2024
90. HE T, Zhang D
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.
    Gut. 2024 Jan 22:gutjnl-2023-331443. doi: 10.1136/gutjnl-2023-331443.
    PubMed    
    
    
    
91. BARCENA-VARELA M, Berraondo P
    Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma.
    Gut. 2024 Jan 9:gutjnl-2023-331647. doi: 10.1136/gutjnl-2023-331647.
    PubMed    
    
    
    
92. 
    Correction: P23 Opportunistic cirrhosis case finding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high-risk group.
    Gut. 2024;73:e3.
    PubMed    
    
    
    
93. KONG M, Zhou J, Kang A, Kuai Y, et al
    Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.
    Gut. 2024 Jan 4:gutjnl-2023-329671. doi: 10.1136/gutjnl-2023-329671.
    PubMed     Abstract available
    
    
    December 2023
94. YANG TC, Chen WC, Hou MC, Chen PH, et al
    Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial.
    Gut. 2023 Dec 14:gutjnl-2023-330419. doi: 10.1136/gutjnl-2023-330419.
    PubMed     Abstract available
    
    
    
95. CAI N, Cheng K, Ma Y, Liu S, et al
    Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8(+) T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.
    Gut. 2023 Dec 13:gutjnl-2023-331342. doi: 10.1136/gutjnl-2023-331342.
    PubMed     Abstract available
    
    
    
96. HEINEN N, Khanal R, Westhoven S, Klohn M, et al
    Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses.
    Gut. 2023 Dec 12:gutjnl-2023-330961. doi: 10.1136/gutjnl-2023-330961.
    PubMed    
    
    
    
97. YU X, Pfefferkorn M, van Bommel F, Zhang X, et al
    Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity.
    Gut. 2023 Dec 11:gutjnl-2023-331217. doi: 10.1136/gutjnl-2023-331217.
    PubMed    
    
    
    
98. CHOUIK Y, Levrero M
    Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block.
    Gut. 2023;73:10-11.
    PubMed    
    
    
    November 2023
99. LI R, Liu X, Huang X, Zhang D, et al
    Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis.
    Gut. 2023 Nov 30:gutjnl-2023-330243. doi: 10.1136/gutjnl-2023-330243.
    PubMed     Abstract available
    
    
    
100. ZHANG X, Yip TC, Wong GL, Leow WX, et al
     Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
     Gut. 2023;72:2364-2371.
     PubMed     Abstract available
     
     
     
101. RODERBURG C, Kostev K, Mertens A, Luedde T, et al
     Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer.
     Gut. 2023;72:2383-2384.
     PubMed    
     
     
     
102. EN LI CHO E, Ang CZ, Quek J, Fu CE, et al
     Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
     Gut. 2023;72:2138-2148.
     PubMed     Abstract available
     
     
     
103. 
     Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
     Gut. 2023;72:e4.
     PubMed    
     
     
     October 2023
104. BRENNAN PN, Zelber-Sagi S, Allen AM, Dillon JF, et al
     Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.
     Gut. 2023 Oct 28:gutjnl-2023-330771. doi: 10.1136/gutjnl-2023-330771.
     PubMed    
     
     
     
105. ARECHEDERRA M, Casadei Gardini A, Raggi C
     More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma.
     Gut. 2023 Oct 27:gutjnl-2023-331119. doi: 10.1136/gutjnl-2023-331119.
     PubMed    
     
     
     
106. JUANOLA A, Ma AT, de Wit K, Gananandan K, et al
     Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.
     Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923.
     PubMed     Abstract available
     
     
     
107. TESTONI B, Scholtes C, Plissonnier ML, Paturel A, et al
     Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
     Gut. 2023 Oct 25:gutjnl-2023-330644. doi: 10.1136/gutjnl-2023-330644.
     PubMed     Abstract available
     
     
     
108. CHOI WM, Kim GA, Choi J, Choi GH, et al
     Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
     Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
     PubMed     Abstract available
     
     
     
109. MUKHOPADHYA I
     Is HBx protein the X factor in the pathogenesis of IBD?
     Gut. 2023;72:1808-1809.
     PubMed    
     
     
     
110. CIOCAN D, Turpin W
     New insights into an old paradigm: why IgA accumulates in alcoholic liver disease and what could be its role.
     Gut. 2023;72:1812-1814.
     PubMed    
     
     
     
111. AVILA MA
     MicroRNA-223: a key regulator of liver tumour microenvironment.
     Gut. 2023;72:1811-1812.
     PubMed    
     
     
     September 2023
112. MANTOVANI A, Tilg H, Targher G
     FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials.
     Gut. 2023 Sep 27:gutjnl-2023-331115. doi: 10.1136/gutjnl-2023-331115.
     PubMed    
     
     
     
113. O'ROURKE CJ, Salati M, Rae C, Carpino G, et al
     Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
     Gut. 2023 Sep 27:gutjnl-2023-330748. doi: 10.1136/gutjnl-2023-330748.
     PubMed     Abstract available
     
     
     June 2023
114. POTENZA A, Balestrieri C, Spiga M, Albarello L, et al
     Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
     Gut. 2023 Jun 30:gutjnl-2022-328042. doi: 10.1136/gutjnl-2022-328042.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.